ÂÜŔňÂŇÂ×

Jeffery Kutok, M.D., Ph.D., is currently the chief scientific officer at Epizyme, Inc., where he directs the company’s scientific strategy, including preclinical research to support the development expansion of TAZVERIK™ (tazemetostat) and the company’s epigenetic pipeline. Dr. Kutok had previously served as executive vice president and chief scientific officer at Infinity Pharmaceuticals, Inc. and was responsible for the scientific strategy, preclinical development, and translational science. Prior to joining Infinity in 2010, Dr. Kutok was an associate professor of pathology at Harvard Medical School and Brigham and Women’s Hospital. His laboratory focused on translational medicine research and biomarker identification in cancer, and he is an author on over 200 journal articles, reviews, and book chapters. Dr. Kutok is board certified in Anatomic Pathology and Hematology and had clinical duties in Hematopathology and Molecular Diagnostics at Brigham and Women’s Hospital. Dr. Kutok received his B.S. in biology and his M.D., Ph.D. in medicine and molecular pathology from the State University of New York at Stony Brook. His Ph.D. was earned working in the laboratory of Dr. Barry Coller, M.D. in the field of platelet pathobiology. He was also a post-doctoral fellow at Harvard University in the laboratory of Dr. Gary Gilliland, M.D., Ph.D.